Please enable JS

Indiana Health Finance Commission Biosimilars Testimony

FILTER BY TYPE

Most Recent

Categories

ARCHIVES

Indiana Health Finance Commission Biosimilars Testimony

Aug 08// Advocate Testimony Biosimilars

GHLF Indiana Health Finance Commission Biosimilars Testimony

READ MORE

Pennsylvania House Biosimilars Testimony

Aug 08// Advocate Testimony Biosimilars

GHLF Pennsylvania House Biosimilars Testimony

READ MORE

GHLF Submits Letter to FDA Requesting Distinguishable Names for Biosimilars

Jan 13// Biosimilars Memos Seth's 50 State Network

On September 26th GHLF submitted a letter to Commissioner Hamburg at the FDA written by GHLF Chief Medical Officer, Dr. Jonathan Krant.  The letter explains that biosimilars are not like generic drugs. A biosimilar product is highly similar to, but not the same as it’s reference biologic product. Therefore, from a patient safety perspective, it is […]

READ MORE

50 State Network Advocate Talking Points: Biosimilars

Jan 04// Biosimilars Seth's 50 State Network Talking Points

As patients, our core concerns are to safeguard safety and the physician-patient relationship. Physicians and their patients are in the best position to determine appropriate therapies

READ MORE